Gleamer vs Rayscape (2026)
Two European radiograph companies reading different films for different departments. Gleamer is trauma first, detecting fractures, effusions and dislocations with a clearance covering adult and pediatric use that is reported to be unique in that segment, aimed at the overnight emergency queue where a missed finding most reliably becomes a complaint. Rayscape is chest first, with a large findings set, longitudinal comparison against prior scans and independent evaluation from a tuberculosis screening deployment. A department choosing between them is choosing which reading burden to attack rather than which vendor is better. Ask each for performance on your own case mix, because prevalence changes the false positive burden more than published sensitivity does.
- Its fracture detection clearance covers both adult and pediatric use, reported to be unique in that segment, with a strong clearance study design behind it.
- Trauma radiography is the highest volume plain film reading in any emergency department and the one where a missed finding most often becomes a claim.
- Distribution runs directly and through several imaging platform partners, so adoption does not depend on one integration path.
- Chest coverage is broad with longitudinal comparison against a patient's prior scans, plus lung nodule work on computed tomography.
- Independent evaluation in a tuberculosis screening context is a harder test than a retrospective reader study.
- On premise and cloud integration are both offered, which matters where images cannot leave the institution.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Gleamer and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Gleamer | Rayscape |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2017 | 2019 |
| Headquarters | Saint-Mandé, France | Timisoara, Romania |
| Website | gleamer.ai | rayscape.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Gleamer SAS is a radiology AI company based in Saint-Mandé, on the edge of Paris, and since 2 March 2026 part of DeepHealth, the digital health subsidiary of the US imaging services operator RadNet, Inc. RadNet announced the all cash acquisition at up to 230 million euros, about 215 million at closing plus a 15 million contingent milestone. Gleamer's site and products keep the Gleamer name.
Source: AI Health Index, August 2026
Romanian imaging AI company based in Timisoara whose Rayscape CXR analyzes chest X-rays, detecting and localizing 148 findings across 17 clinical classes, including tuberculosis, with bone suppressed views, an automatic cardiothoracic ratio and a normal or abnormal flag for worklist prioritization, and whose lung CT product detects nodules and compares them against a patient's prior scans. Its tuberculosis detection was evaluated independently in a South African tuberculosis prevalence survey published in The Lancet Digital Health in 2024.
Source: AI Health Index, August 2026
Questions buyers ask
How do Gleamer and Rayscape work with the EHR?
Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, since March 2026, and nothing published says whether the products now run inside DeepHealth's platform or remain available on other vendors' archives.
Rayscape CXR integrates with the archive over DICOM, on premises or with a cloud archive, returning annotated images and structured outputs inside the native radiology viewer without a separate workspace, and sites can configure outputs, thresholds and visualization to their own reporting standards. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Gleamer and Rayscape priced and sold?
In Gleamer's case, the packaging and the owner are public. The products are sold as modules of the Gleamer Copilot suite, and since March 2026 Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, so contracting may run through DeepHealth.
The company's site has a pricing and plans page, and its AWS Marketplace listing for Rayscape CXR shows a free subscription with no end date alongside a 30 day money back guarantee on the current annual term, which suggests a paid annual contract behind the listing without stating its price or unit. The product can be procured through the marketplace and directly. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Gleamer and Rayscape handle patient data?
When Gleamer receives patient data from a customer, including imaging examinations and reports, it acts as the customer's processor and works on pseudonymized data, and where the customer authorizes it, Gleamer may anonymize pseudonymized patient data and use the anonymized result for its own purposes, including training and developing its products.
In Rayscape's case, the company's AWS Marketplace listing describes the product as software as a service, which sits uneasily with data never leaving the institution, and nothing says which deployments the commitment covers. Support, diagnostic and incident access usually carries exceptions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Gleamer and Rayscape cover?
For Gleamer, the suite now claims far wider coverage, described by the company as covering all imaging modalities, with products for chest X-ray, chest CT, bone CT, breast imaging, brain MRI and lumbar spine MRI. Validation for those is not summarized on the home page, and ChestView and BoneMetrics have their own FDA summaries.
With Rayscape, the tuberculosis use has independent validation in a South African prevalence survey (The Lancet Digital Health, 2024), a population screening setting; the broader findings set and the CT product have no published per finding validation. The company reports clinical use at more than 300 sites in 18 countries, and its customer stories describe emergency and outpatient deployments. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Compare these per body region and per finding rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface and their findings counts are not comparable. Neither publishes a security attestation or trust center, which this index records as a pattern across non United States imaging vendors rather than a fault of either. Gleamer's multi party distribution makes data stewardship harder to answer, since the responsible party varies by delivery path and no business associate terms were located.